VANGUARD GROUP INC 13D and 13G filings for Relmada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:13 pm Sale |
2023-12-29 | 13G | Relmada Therapeutics, Inc. RLMD |
VANGUARD GROUP INC | 1,310,805 4.350% |
-206,175 (-13.59%) |
Filing |
| 2023-02-09 11:30 am Purchase |
2022-12-30 | 13G | Relmada Therapeutics, Inc. RLMD |
VANGUARD GROUP INC | 1,516,980 5.040% |
1,516,980 (New Position) |
Filing |